Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bleomycetin antitumor activity in relation to solid mouse tumors].

V S Bazhanov, V A Shorin

    Antibiotiki
    |September 1, 1981
    PubMed
    Summary

    Bleomycetin demonstrated selective antitumor activity, particularly against sarcoma 180. However, it showed limited efficacy against other tested cancers, with no route of administration advantage observed.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Antiviral activity and therapeutic characteristics of the antibiotic antivirubin].

    Antibiotiki·2014
    Same author

    [Pharmacological properties of colimycin].

    Antibiotiki·2014
    Same author

    [New antibiotic actinoidin].

    Antibiotiki·2014
    Same author

    [Crystallomycin, a new antibacterial antibiotic].

    Antibiotiki·2014
    Same author

    [Coerulomycin, a new antiviral antibiotic produced by Actinomyces coerulescens].

    Antibiotiki·2014
    Same author

    [New anti-viral antibiotic heliomycin].

    Antibiotiki·2014

    Area of Science:

    • Oncology
    • Pharmacology
    • Cancer Research

    Background:

    • Bleomycetin (bleomycin A5) is an antibiotic with known cytotoxic properties.
    • Understanding the selective antitumor activity of bleomycetin is crucial for optimizing cancer therapy.

    Purpose of the Study:

    • To evaluate the antitumor efficacy of bleomycetin against various cancer models.
    • To compare the effectiveness of different administration routes for bleomycetin.

    Main Methods:

    • In vivo studies were conducted using sarcoma 180, Garding-Passey melanoma, cervical carcinoma CC-5, and lymphosarcoma L10-1.
    • Bleomycetin was administered via intravenous and subcutaneous routes.

    Main Results:

    • Bleomycetin exhibited significant selective antitumor activity against the solid form of sarcoma 180.
    • Lower activity was observed against Garding-Passey melanoma and cervical carcinoma CC-5.
    • Lymphosarcoma L10-1 demonstrated the highest resistance to bleomycetin.
    • No significant difference in efficacy was found between intravenous and subcutaneous administration.

    Conclusions:

    • Bleomycetin possesses selective antitumor properties, with notable efficacy against sarcoma 180.
    • The drug's effectiveness varies across different cancer types, with lymphosarcoma L10-1 being highly resistant.
    • Administration route does not appear to influence bleomycetin's overall therapeutic effect.

    Related Experiment Videos